Can the Safe Surgical Margin Be Narrowed in Early-Stage... : Advances in Skin & Wound Care (2024)

INTRODUCTION

Among the nonmelanoma skin tumors, basal cell carcinoma (BCC) and squamous cell carcinoma are the most common;1,2 BCCs constitute the majority of these tumors. Although BCCs can occur at any age, incidence increases with older age. The most common etiologic factors are sunlight and UV light exposure, fair skin, immunosuppression, radiotherapy, and genetic factors.3 In both men and women, 80% of nonmelanoma skin tumors develop in the face, head, and neck region.4

A BCC is diagnosed by histopathologic evaluation after excision of the lesion. There are several histologic subtypes of BCC: nodular, superficial, infiltrative, sclerosing, and mixed forms are the most common subtypes. All subtypes have peripheral palisaded hyperchromatic nuclei, narrow cytoplasm, and artifactual retraction of the stroma around the tumor islands,5 but the prognosis of each subtype can differ. Cutaneous tumors that are less than 2 cm in diameter are considered early-stage tumors.

Surgical excision with a safe margin is the most common and effective treatment for BCC. The size, localization, and histologic subtype of the tumor are important in determining the adequate surgical margin. Recommended surgical margins are 2 to 5 mm in low-risk BCCs and 5 to 15 mm in high-risk BCCs.6 Although BCCs grow slowly and rarely metastasize, they can cause extensive tissue destruction, especially on the face, if they are left untreated or are inadequately treated. A BCC may be considered high risk if it is located in the ear or in the middle of the face.3

It is difficult to reconstruct BCC-related defects in the facial region, especially around the natural orifices. Factors such as invasion of vital structures, histopathologic subtype, patient age, general condition, and cosmetic concerns all play an important role in determining the treatment modality. Depending on these conditions, it may be necessary to apply narrower surgical margins with complete tumor removal. Risk factors for inadequate surgical excision are tumor localization (ear, mid-face), tumor histology, and tumor size (>20 mm).7,8

Previous research has aimed to understand relationships among BCC subtypes with dermoscopic appearance and clinical features.9 In the present study, the authors (1) examined the relationships among positive surgical margin and age, sex, tumor location, comorbid diseases, tumor size, and tumor thickness in BCC in the facial region and (2) investigated whether the surgical margin value can be narrowed in early-stage facial BCCs.

METHODS

Ethics

Ethics approval for this retrospective cross-sectional study was granted by the ethics committee of Bandırma Onyedi Eylül University Faculty of Medicine (approval no. 2022/4-5).

Participants

The study population included patients who underwent an operation in the face region at the study hospital between January 2018 and January 2022. Patients were included in the study if they were older than 18 years, they had at least 1 year of postoperative follow-up, and their pathology was reported as BCC. Pediatric patients, those whose pathology report did not indicate BCC, those who were diagnosed with incisional biopsy but were not operated on, patients with relapses or advanced tumors (tumor size >2 cm), and patients who were not followed up were excluded from the study.

Two researchers reviewed patient charts from their hospital files and recorded the following characteristics: age, sex, comorbid diseases (hypertension, diabetes mellitus [DM], cardiac diseases, and other), surgical notes, place of residence (rural or urban), pathology reports, tumor diameter and thickness, the condition of the surgical margin, tumor subtype, the surgical technique (primary or local flap repair), and tumor localization. Patient data were stored in a computer system that was accessed with the permission of the hospital management.

Operations were performed in the OR. Before beginning the operation, the lesion was examined under a surgical microscope, and the borders of the tumor were determined. Frozen sections were not used. Values reported as surgical margins represent the histologic margins made by the pathology department. Tumor localization was classified as forehead, periocular, periauricular, nasal (tip, alar, and dorsum), and cheek-malar (zygoma, nasolabial sulcus, temporal) regions.

Patient Grouping

The recorded subtypes of BCC were nodular, superficial, nodular-infiltrative, nodular-micronodular, nodular-sclerosing, infitrative, and micronodular. The authors categorized patients into three groups based on tumor subtype and prognosis: nodular and superficial subtypes with good prognosis (group 1); nodular-infiltrative, nodular-micronodular, and nodular-sclerosing subtypes with mixed prognosis (group 2); and infiltrative and micronodular subtypes with poor prognosis (group 3).

Histopathologic Examination

Specimens had previously been sliced into 4-μm-thick sections and stained with hematoxylin-eosin. For histopathologic examination, all hematoxylin-eosin-stained slides were reexamined (magnification ×400) and subtyped by a single pathologist with the permission of the department and in accordance with the World Health Organization 2018 Skin Tumors Classification.10 The largest diameter of the tumor and the closest distance to the surgical margin were measured and recorded. Tumor thickness was measured from the granular layer of the epidermis to the deepest point of the tumor. Only the longest diameter and the thickness were evaluated because the tumors were asymmetrical.

Statistical Analysis

The authors used SPSS for Windows (IBM Corp) for statistical analysis. Outcomes were presented as median and interquartile range (IQR) or mean and SD for numerical variables, and as frequency and percentage for categorical data. The normality of the data was evaluated with the Shapiro-Wilk test. The authors used one-way analysis of variance or the Kruskal-Wallis test for multiple comparisons and an independent-samples t test or a Mann-Whitney U test for pairwise comparisons (depending on their distribution). Categorical variables were compared via the χ2 test or Fisher exact test. The statistical significance threshold was accepted as P < .05.

RESULTS

A total of 95 patients (47 men) with a mean age of 70.4 ± 11.4 years (range, 38–96 years) were included in the study. Regarding patient characteristics, 45.5% of the patients lived in rural areas and 54.5% lived in urban areas, 53.7% had hypertension, 13.7% had DM, 27.4% had cardiac diseases, and 23.2% had other comorbidities. When these data were compared with the positive surgical margin, there were no statistically significant differences (Table 1).

Table 1. - PARTICIPANT CHARACTERISTICS ACCORDING TO POSITIVE SURGICAL MARGIN

Characteristic Positive Surgical Margin Test Value P
Present Absent
Sex, n (%) 0.080a .777
 Male 5 (45.5) 42 (50.0)
 Female 6 (54.5) 42 (50.0)
Residence, n (%) 0.302b .743
 Rural 5 (45.5) 31 (36.9)
 Urban 6 (54.5) 53 (63.1)
Hypertension, n (%) 0.004a .951
 Absent 5 (45.5) 39 (46.4)
 Present 6 (54.5) 45 (53.6)
Diabetes mellitus, n (%) 0.213b .644
 Absent 9 (81.8) 73 (86.9)
 Present 2 (18.2) 11 (13.1)
Cardiac disease, n (%) 0.506b .486
 Absent 7 (63.6) 62 (73.8)
 Present 4 (36.4) 22 (26.2)
Other diseases, n (%) 0.118b .713
 Absent 8 (72.7) 65 (77.4)
 Present 3 (27.3) 19 (22.6)
Age, mean (SD), y 74 (10.2) 69.9 (11.5) 1.097c .276
Tumor size, median (IQR), cm 1.2 (0.7–1.7) 1.5 (1–2) 0.940d .347
Tumor thickness, median (IQR), mm 2 (2–3) 3 (2–4) 0.441d .659

Abbreviation: IQR, interquartile range.

aχ2 Test.

bFisher exact test.

cIndependent-samples t test.

dMann-Whitney U test.

The most common tumor subtype was the nodular form (46.3%), followed by the nodular-micronodular type (24.2%); the superficial type was the least common subtype (4.2%). The positive surgical margin occurred at the highest rate (54.5%) in mixed forms.

Group 1 included 48 patients, group 2 included 32 patients, and group 3 included 15 patients. There were no statistically significant between-group differences in age, sex, tumor localization, comorbid diseases, place of residence, surgical technique, or tumor size (Table 2).

Table 2. - PARTICIPANT CHARACTERISTICS ACCORDING TO TUMOR SUBTYPE

Characteristic Tumor Subtype Test Value P
Good Prognosis Mixed Prognosis Poor Prognosis
Method, n (%) 1.217a .544
 Primary repair 20 (41.7) 17 (53.1) 6 (40.0)
 Repair with flap 28 (58.3) 15 (46.9) 9 (60.0)
Sex, n (%) 2.718a .249
 Male 24 (50.0) 13 (40.6) 10 (66.7)
 Female 24 (50.0) 19 (59.4) 5 (33.3)
Tumor localization, n (%) 3.631b .910
 Forehead 7 (14.6) 3 (9.4) 2 (13.3)
 Periocular 6 (12.5) 5 (15.6) 1 (6.7)
 Periauricular 7 (14.6) 6 (18.8) 2 (13.3)
 Nasal dorsum 15 (31.3) 13 (40.6) 5 (33.3)
 Cheek-malar 13 (27.1) 5 (15.6) 5 (33.3)
Positive surgical margin, n (%) 5.638b .046
 Present 2 (4.2)c 6 (18.8)c 3 (20.0)c
 Absent 46 (95.8)c 26 (81.3)c 12 (80.0)c
Residence, n (%) 5.000a .082
 Rural 13 (27.1) 15 (46.9) 8 (53.3)
 Urban 25 (72.9) 17 (53.1) 7 (46.7)
Hypertension, n (%) 1.283a .527
 Present 24 (50.0) 17 (53.1) 10 (66.7)
 Absent 24 (50.0) 15 (46.9) 5 (33.3)
Diabetes mellitus, n (%) 0.165b 1.000
 Present 7 (14.6) 4 (12.5) 2 (13.3)
 Absent 41 (85.4) 28 (87.5) 13 (86.7)
Cardiac disease, n (%) 5.108a .078
 Present 14 (29.2) 5 (15.6) 7 (46.7)
 Absent 34 (70.8) 27 (84.4) 8 (53.3)
Other diseases, n (%) 0.966a .617
 Present 12 (25.0) 8 (25.0) 2 (13.3)
 Absent 36 (75.0) 24 (75.0) 13 (86.7)
Age, mean (SD), y 68.7 (11.4) 72 (12.0) 71.2 (9.8) 1.161d .318
Tumor size, median (IQR), cm 1.1 (0.8-2) 1.7 (1.0–2) 1.2 (1–2) 2.345e .310

Abbreviation: IQR, interquartile range.

aχ2 Test.

bFisher exact test.

cDenotes a subset of tumor subtype categories whose column proportions do not differ significantly from each other at the P < .05 level (surgical margin continuity differed when compared with the Fisher exact test according to tumor subtype, but this differentiation disappeared after Bonferroni correction).

dOne-way analysis of variance.

eKruskal-Wallis test.

The mean surgical margin was 0.2 cm (IQR, 0.1–0.3 cm) in group 1, 0.1 cm (IQR, 0.05–0.2 cm) in group 2, and 0.1 cm (IQR, 0.05–0.3 cm) in group 3. In comparing these values, the surgical margin distance was greater in group 1 than in the other groups (P = .007; Table 3). Tumor thickness was 2 mm (IQR, 0.1–0.3 mm) in group 1, 3 mm (IQR, 2–4 mm) in group 2, and 3 mm (IQR, 2–5 mm) in group 3. The mean tumor thickness in group 1 was lower than those of the other groups (P = .020; Table 3). A total of 26 patients had tumors larger than 20 mm, and positive surgical margins were detected in only 2 of them.

Table 3. - COMPARISON OF SURGICAL MARGINS AND TUMOR THICKNESS BY TUMOR SUBTYPE

Characteristics Good Prognosis, Median (IQR) Mixed Prognosis, Median (IQR) Poor Prognosis, Median (IQR) Kruskal-Wallis test P
Surgical margin, cm 0.2 (0.1–0.3) 0.1 (0.05–0.2) 0.1 (0.05–0.3) 9.946 .007
Tumor thickness, mm 2 (2–3) 3 (2–4) 3 (2–5) 7.875 .020

Abbreviation: IQR, interquartile range.

In terms of tumor localization, BCCs were located in the nasal region in 33 patients, in the cheek and malar region in 23 patients, in the forehead in 12 patients, in the periauricular region in 15 patients, and in the periocular regions in 12 patients. Primary repair was performed in 43 patients after tumor excision, whereas local flap repair was performed in 52 patients. Surgical margins were reported as positive in five patients who underwent primary repair (11.6%; two in the nasal region, two in the periauricular, and one in the periocular) and in six patients who underwent local flap repair (11.5%; three in the nasal region, two in the cheek and malar region, and one in the frontal region). In comparing surgical techniques (primary vs local flap repair), the only factor that varied significantly between them was tumor localization (P < .001; Table 4).

Table 4. - COMPARISON OF PARTICIPANT CHARACTERISTICS REGARDING THE SURGICAL METHOD

Characteristic Surgical Method Test Value P
Primary Repair Local Flap Repair
Sex, n (%) 0.090a .765
 Male 22 (51.2) 25 (48.1)
 Female 21 (48.8) 27 (51.9)
Positive surgical margin, n (%) 0.000b 1.000
 Present 5 (11.6) 6 (11.5)
 Absent 38 (88.4) 46 (88.5)
Tumor localization, n (%) 32.304a <.001
 Forehead 7c (16.3) 5c (9.6)
 Periocular 8c (18.6) 4c (7.7)
 Periauricular 15c (34.9) 0d (0.0)
 Nasal dorsum 7c (16.3) 26d (50.0)
 Cheek-malar 6c (14.0) 17d (32.7)
Tumor subtype, n (%) 1.217a .544
 Good prognosis 20 (46.5) 28 (53.8)
 Mixed prognosis 17 (39.5) 15 (28.8)
 Poor prognosis 6 (14.0) 9 (17.3)
Hypertension, n (%) 0.627a .428
 Present 25 (58.1) 26 (50.0)
 Absent 18 (41.9) 26 (50.0)
Diabetes mellitus, n (%) 0.005a .945
 Present 6 (14.0) 7 (13.5)
 Absent 37 (86.0) 45 (86.5)
Cardiac disease, n (%) 0.668a .414
 Present 10 (23.3) 16 (30.8)
 Absent 33 (76.7) 36 (69.2)
Other diseases n (%) 0.259a .611
 Present 11 (25.6 11 (21.2)
 Absent 32 (74.4) 41 (78.8)
Age, mean (SD), y 68.4 (12.8) 66 (11.9) 0.460e .650
Tumor size, median (IQR), cm 1.2 (0.7-2) 1.5 (1–2.1) 1.573f .116
Surgical margin, median (IQR), cm 0.1 (0.05-0.2) 0.2 (0.1–0.3) 1.579f .114
Tumor thickness, median (IQR), mm 3 (2–3) 2.5 (2–4) 0.146f .884

Abbreviation: IQR, interquartile range.

aχ2 Test.

bFisher exact test.

cDenotes a subset of method categories whose column proportions do not differ significantly from each other at the P < .05 level.

dDenotes a subset of method categories whose column proportions do not differ significantly from each other at the P < .05 level.

eIndependent-samples t test.

fMann-Whitney U test.


DISCUSSION

Basal cell carcinoma is a common, slow-growing, locally infiltrative malignant tumor that rarely metastasizes and shows basaloid differentiation. Annual incidence varies by country but ranges between 0.07% and 1%.11 Basal cell carcinoma develops from follicular and interfollicular keratinocyte stem cells12,13 and is frequently seen in older adults. Roudier-Pujol et al14 reported that BCC in young patients is not more aggressive than in older patients.14 Studies have also reported that there are no differences between young and old patients in terms of histologic subtypes.15,16

With aging, exposure to the sun and UV light increases cumulatively, and the immune system weakens. This may lead to increasing incidence of BCC with aging. The longer the sun exposure, the greater the risk of BCC. In addition, individuals who live in rural areas may have difficulty reaching the hospital, causing BCCs in this population to be diagnosed at a more advanced stage. However, fewer than half of the patients (45.5%) lived in rural areas in the present study. The reason for this may be that the rural areas in the study region are close to the downtown and the hospitals, and the region receives less sunlight than the southern parts of the country.

The histologically different subtypes of BCC have different prognostic features.11 In the study by de Godoy et al,17 the nodular type was the most common, and the superficial type was the second most common.17 However, tumor persistence at the surgical margin was significantly higher in the high-risk group.17 In the study by Girardi et al,18 the most common subtypes were nodular and basosquamous forms, and the positive surgical margin was significantly higher in the aggressive forms.18 In the present study, the most common subtype was the nodular form (46.3%), followed by the nodular-micronodular type (24.2%); the superficial type was the least common subtype (4.2%). Unlike the literature, the positive surgical margin was found at the highest rate (54.5%) in mixed forms. All of the mixed forms had nodular components. The predominance of this subtype, which is an indicator of poor prognosis, in mixed forms of tumors may explain the high rate of positive surgical margin in the mixed group. Whereas the positive surgical margin rate was low in the good prognosis group, it was higher in the mixed group and highest in the poor prognosis group. In addition, there was a significant relationship in terms of the distance of the tumor to the surgical margin among the groups.

Depending on the characteristics of the tumor (size, location, recurrence, histologic subtype), ablative treatments, standard excision, or Mohs micrographic surgery (MMS) can be performed. Because ablative treatments do not have histopathologic control, they have a high risk of recurrence; this method may be preferred in low-risk BCCs. In unfavorable locations, or in the case of incompletely removed BCCs, recurrent BCCs, or large BCCs, MMS is preferred.19 Because these patients were not included in the present study, MMS was not performed. However, studies comparing standard excision and MMS for BCCs in the head and neck region have suggested that MMS should primarily be used for high-risk BCCs because of its high cost.20,21 In the study by Smeets et al,22 although the recurrence rate after MMS was lower in facial BCCs compared with standard excision, the difference was not statistically significant.

One of the most important factors determining the positive surgical margin in BCC excision is the area of the intact tissue. In histopathologic analyzes, a tumor-free area of at least 1 mm is suitable microscopically for complete resection.18 However, in two different studies, a recurrence rate of 18% was found in facial BCCs with a 1- to 2-mm surgical margin.23,24 In another study in which 134 facial BCCs were examined, the authors reported that the surgical margin of 1 to 3 mm was insufficient.25 Nahhas et al26 recommended a 4-mm surgical margin using standard excision for low-risk BCCs. Those authors also suggested having a surgical margin greater than 4 mm when using MMS for high-risk BCCs and noted that standard excision could be used as an alternative.26 Dermatologic surgeons may prefer narrower surgical margins (<4 mm) in excision to reduce the defect area and avoid needing a flap or grafts.

Surgical margins of 4 mm cannot always be applied for excision in facial BCCs. Various studies have reported positivity of surgical margins after excision in facial BCCs at a rate of 16% to 18%.23,27,28 The high rate of positive surgical margins for these excised BCCs may be due to the mixed histologic pattern of tumors. Even if the surgical margins are well-demarked macroscopically, subepidermal finger-like extensions of the tumor at the microscopic level may be the reason for the positive surgical margins. In such cases, MMS may be preferred.

In the present study, the surgical margin was 2 mm on average. This value is lower than those reported in the literature, and the positive surgical margin rate (11.57%) was lower as well. This may be due to the frequency of such surgeries in the authors’ clinic and the practice of using a microscope to determine the surgical margins preoperatively, especially with tumors that have irregular borders. Similarly, Quazi et al29 reported that the excision margin could be 2 mm in well-demarked BCCs, and Thomas et al30 found that it could be 3 mm. Herzum et al31 reported that BCC excision at 3 mm may be appropriate in the head and neck for small, well-defined, and nonaggressive BCCs with surgical cure rates of 100% and 1.5% recurrences. However, they recommended that 1- to 2-mm surgical margins should be performed for BCCs in difficult-to-treat areas because the surgical cure rate was only 93%.31

Tumor localization can affect decisions regarding which surgical technique to use, as indicated in the present study. Defects near the natural orifices and areas where the skin has more tension are difficult to reconstruct, which may lead to inadequate excision of the tumor. For example, the surgical margin positivity rate is 52% after BCC excision in the periocular region.32 Positive surgical margin rates may differ by tumor localization, but there is no consensus regarding what constitutes adequate surgical margin in each localization. In the present study, local flap repair was performed most often in the nasal and cheek and malar regions, whereas primary repair was performed most often in other regions.

Tumor localization is not the only factor that impacts treatment options for facial BCCs; surgical techniques may also vary based on the patient’s cosmetic concerns. Tumors with graft and/or flap repair are often large, and positive surgical margins may be seen more frequently. If the tumor is larger than 20 mm, this may be a risk factor for inadequate excision.7 However, in the present study, 26 patients had tumors that were larger than 20 mm, and positive surgical margins were detected in only 2 of them. Careful preoperative planning (dermoscopic or microscopic examination) can prevent inadequate excisions in large tumors. Inadequate excision in large tumors may be prevented by different surgeons performing the excision and reconstruction. Frozen section examination in suspicious cases can also significantly reduce the positivity of surgical margins.

Limitations

The fact that MMS was not perfomed in some BCC tumor localizations where it is recommended may be a limitation of this study. Another limitation is that advanced-stage tumors were not included in the study.

CONCLUSIONS

Different histologic subtypes of BCC show different prognostic features. Tumor thickness, tumor localization, and adequate surgical margins at the excision are important factors for the prevention of recurrences and regional tumor control. To prevent positive surgical margins, surgeons should individually plan the treatment of each patient according to the tumor characteristics and the patient’s risk factors. With further research, adequate surgical margin values may change in early-stage facial BCCs and will standardize according to tumor localization. Preoperative macroscopic evaluation of the tumor margins with a surgical microscope may decrease the positive surgical margin rates. The surgical margin, which the literature recommends be approximately 4 or 5 mm, could potentially be narrowed to 2 mm in early-stage facial BCCs.

REFERENCES

1. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology, clinical and histological subtypes; and disease associations. J Am Acad Dermatol 2019;80(2):303–17.

2. Ho T, Byrne PJ. Evaluation and initial management of the patient with facial skin cancer. Facial Plast Surg Clin North Am 2009;17(3):301–7.

3. Newlands C, Currie R, Memon A, Whitaker S, Woolford T. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(S2):125–32.

4. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30(5):774–8.

5. Seidl-Philipp M, Frischhut N, Höllweger N, Schmuth M, Nguyen VA. Known and new facts on basal cell carcinoma. J Dtsch Dermatol Ges 2021;19(7):1021–41.

6. Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019;118:10–34.

7. Su SY, Giorlando F, Ek EW, Dieu T. Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg 2007;120(5):1240–8.

8. Kumar P, Watson S, Brain AN, et al. Incomplete excision of basal cell carcinoma: a prospective multicentre audit. Br J Plast Surg 2002;55(8):616–22.

9. Pyne JH, Myint E, Barr EM, Clark SP, Hou R. Basal cell carcinoma: variation in invasion depth by subtype, sex, and anatomic site in 4,565 cases. Dermatol Pract Concept 2018;8(4):314–9.

10. Messina J, Epstein EH Jr, Kossard S. Basal cell carcinoma. In: Elder DE, Massi D, Scolyer RA, Willemze R, eds. World Health Organization Classification of Skin Tumours. Lyon, France: IARC Press; 2018:26–34.

  • Cited Here

11. Basset-Seguin N, Herms F. Update in the management of basal cell carcinoma. Acta Derm Venereol 2020;100(11):adv00140.

12. Wang GY, So P-L, Wang L, Libove E, Wang J, Epstein EH. Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis. J Invest Dermatol 2011;131(11):2298–305.

13. Youssef KK, van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010;12(3):299–305.

14. Roudier-Pujol C, Auperin A, Nguyen T, Duvillard P, Benhamou E, Avril M. Basal cell carcinoma in young adults: not more aggressive than in older patients. Dermatology 1999;199(2):119–23.

15. Milroy CJ, Horlock N, Wilson GD, Sanders R. Aggressive basal cell carcinoma in young patients: fact or fiction? Br J Plast Surg 2000;53(5):393–6.

16. Leffell DJ, Headington JT, Wong DS, Swanson NA. Aggressive-growth basal cell carcinoma in young adults. Arch Dermatol 1991;127(11):1663–7.

17. De Godoy CAP, de Oliveira Neta AL, Leão SSS, Dantas RL, Carvalho VOF, da Silva SF. Evaluation of surgical margins according to the histological type of basal cell carcinoma. An Bras Dermatol 2017;92(2):226–30.

18. Girardi FM, Wagner VP, Martins MD, Abentroth AL, Hauth LA. Factors associated with incomplete surgical margins in basal cell carcinoma of the head and neck. Braz J Otorhinolaryngol 2021;87(6):695–701.

19. Vuyk HD, Lohuis PJ. Mohs micrographic surgery for facial skin cancer. Clin Otolaryngol Allied Sci 2001;26(4):265–73.

20. Alsaif A, Hayre A, Karam M, Rahman S, Abdul Z, Matteucci P. Mohs micrographic surgery versus standard excision for basal cell carcinoma in the head and neck: systematic review and meta-analysis. Cureus 2021;13(11):e19981.

21. Essers BA, Dirksen CD, Nieman FH, et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 2006;142(2):187–94.

22. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004;364(9447):1766–72.

23. Niederhagen B, von Lindern JJ, Berge S, Appel T, Reich RH, Kruger E. Staged operations for basal cell carcinoma of the face. Br J Oral Maxillofac Surg 2000;38(5):477–9.

24. Hsuan JD, Harrad RA, Potts MJ, Collins C. Small margin excision of periocular basal cell carcinoma: 5 year results. Br J Ophthalmol 2004;88(3):358–60.

25. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH. Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol 2005;53(3):464–8.

26. Nahhas AF, Scarbrough CA, Trotter S. A review of the global guidelines on surgical margins for nonmelanoma skin cancers. J Clin Aesthet Dermatol 2017;10(4):37–46.

27. Fleischer AB Jr, Feldman SR, Barlow JO, et al. The specialty of the treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma: results from a multi-institutional retrospective study. J Am Acad Dermatol 2001;44(2):224–30.

28. Hallock GG, Lutz DA. A prospective study of the accuracy of the surgeon’s diagnosis and significance of positive margins in nonmelanoma skin cancers. Plast Reconstr Surg 2001;107(4):942–7.

29. Quazi SJ, Aslam N, Saleem H, Rahman J, Khan S. Surgical margin of excision in basal cell carcinoma: a systematic review of literature. Cureus 2020;12(7):e9211.

30. Thomas DJ, King AR, Peat BG. Excision margins for nonmelanotic skin cancer. Plast Reconstr Surg 2003;112(1):57–63.

31. Herzum A, Burlando M, Tavilla PP, et al. Dermatoscopically narrowed surgical margins for head and neck basal cell carcinoma: a retrospective case-control study. J Dtsch Dermatol Ges 2022;20(6):807–16.

32. Spraul CW, Ahr WM, Lang GK. Charakterisierung von 141 periokulären Primärbasaliomen und ihre Rezidivhäufigkeit nach chirurgischer Exzision [Clinical and histologic features of 141 primary basal cell carcinomas of the periocular region and their rate of recurrence after surgical excision]. Klin Monbl Augenheilkd 2000;217(4):207–14.

Keywords:

basal cell carcinoma; early stage; facial region; histologic subtype; prognosis; surgical margin

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Can the Safe Surgical Margin Be Narrowed in Early-Stage... : Advances in Skin & Wound Care (2024)
Top Articles
Latest Posts
Article information

Author: Kimberely Baumbach CPA

Last Updated:

Views: 5605

Rating: 4 / 5 (61 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Kimberely Baumbach CPA

Birthday: 1996-01-14

Address: 8381 Boyce Course, Imeldachester, ND 74681

Phone: +3571286597580

Job: Product Banking Analyst

Hobby: Cosplaying, Inline skating, Amateur radio, Baton twirling, Mountaineering, Flying, Archery

Introduction: My name is Kimberely Baumbach CPA, I am a gorgeous, bright, charming, encouraging, zealous, lively, good person who loves writing and wants to share my knowledge and understanding with you.